{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T05:01:37Z","timestamp":1794114097956,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1136\/annrheumdis-2012-201601","type":"journal-article","created":{"date-parts":[[2012,6,24]],"date-time":"2012-06-24T00:56:20Z","timestamp":1340499380000},"page":"863-869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":257,"title":["Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study"],"prefix":"10.1016","volume":"72","author":[{"given":"Mark C","family":"Genovese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Mazurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A","family":"Aelion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Heon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Codding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hugot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephard","family":"Mpofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2012-201601_bib1","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2012-201601_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2012-201601_bib3","first-page":"2521","article-title":"Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients","volume":"29","author":"Sokka","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2012-201601_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2010.25.1.1","article-title":"Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis","volume":"25","author":"Storage","year":"2010","journal-title":"Korean J Intern Med"},{"key":"10.1136\/annrheumdis-2012-201601_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/PPA.S5835","article-title":"Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy","volume":"3","author":"Barton","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"10.1136\/annrheumdis-2012-201601_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrrheum.2009.179","article-title":"IL-17 as a future therapeutic target for rheumatoid arthritis","volume":"5","author":"van den Berg","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/annrheumdis-2012-201601_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(03)00002-9","article-title":"Interleukin-17 family and IL-17 receptors","volume":"14","author":"Moseley","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1136\/annrheumdis-2012-201601_bib8","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1\u03b2 and TNF-\u03b1, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2012-201601_bib9","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"10.1136\/annrheumdis-2012-201601_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1136\/annrheumdis-2012-201601_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/ar294","article-title":"IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis","volume":"3","author":"Chabaud","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1136\/annrheumdis-2012-201601_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/cyto.2001.0939","article-title":"Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo","volume":"16","author":"Cai","year":"2001","journal-title":"Cytokine"},{"key":"10.1136\/annrheumdis-2012-201601_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00018-003-3228-z","article-title":"Interleukin-17: a mediator of inflammatory responses","volume":"61","author":"Witowski","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1136\/annrheumdis-2012-201601_bib14","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/art.10816","article-title":"Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy","volume":"48","author":"Miossec","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib16","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune einduction of collageninduced arthritis in Il\u201317 deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2012-201601_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/art.10173","article-title":"Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with IL-17 receptor IgG1 Fc fusion protein","volume":"46","author":"Bush","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti\u2013murine interleukin\u201317 antibody after the onset of collagen induced arthritis reduces joint inflammation, cartilage destruction and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1136\/annrheumdis-2012-201601_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 3","key":"10.1136\/annrheumdis-2012-201601_bib22","first-page":"125","article-title":"AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind, proof-of-concept trial","volume":"68","author":"Tak","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-201601_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2012-201601_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-201601_bib25","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724214692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724214692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2012-201601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:34:50Z","timestamp":1737250490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724214692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0003496724214692"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-201601","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-201601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 \u00a9 2013 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}